There are many conditions which can be cured or at least ameliorated with a stem cell transplant or an organ transplant. But even when the right donor is available, and…
Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which donor immune cells attack the recipient's tissues. The graft cells recognize…
Following allogeneic hematopoietic stem cell transplant (allo-HCT), which uses healthy stem cells from a donor, many doctors prescribe antibiotics to patients as a protective measure. Many individuals become neutropenic…
According to a story from koin.com, graft-versus-host disease is a condition that can affect recipients of stem cell or organ transplants. Dr. Corey Cutler, Medical Director, Stem Cell Transplant Program,…
The American Society of Hematology (ASH) held its 64th Annual Meeting from December 10-13, 2022. During the meeting, doctors, researchers, and other stakeholders within the hematology sphere came together to…
Research has shown that up to 70% of individuals who undergo stem cell transplantation experience organ damage within just a few months. Many develop graft-versus-host disease (GvHD), a complication in…
According to a video posted on Targeted Oncology, adverse events are a significant concern for people that are receiving treatment for the chronic form of graft-versus-host disease. In the video,…
Every year almost half of the fourteen thousand patients who have received bone marrow or stem cell transplants will develop chronic graft-versus-host disease (cGVHD). Currently, there are no options…
Have you ever heard of the cytokines interleukin-6 (IL-6) or TNF? Normally, these cytokines, excreted by the immune system, may influence autoimmunity or immune responses to foreign invaders. For…
Gareth Crabb is a thoughtful and caring six-year-old boy from Swansea, U.K. He is spending his second Christmas in the hospital this year, as he has anaplastic large cell…
According to a recent article at Targeted Oncology, the FDA has approved abatacept (Orencia) under priority review for preventing moderate to severe acute graft versus host disease (GvHD). The patients…
Normally, the standard FDA review process for potential drugs or biologics takes around 10 months to complete. However, when a drug receives Priority Review status, it means that the FDA…
In some cases, serious complications occur following allogeneic stem cell or bone marrow transplants. For example, in patients with Graft-versus-host disease (GvHD), the donor cells may recognize patient cells as…
According to a June 11 press release from biotechnology company Equillium, Inc. ("Equillium"), positive topline data is now available from the Phase 1b EQUATE clinical trial. Within the clinical trial,…
In a recent press release, biotech company AltruBio Inc. shared that its therapy neihulizumab (AbGn-168H) received Fast Track designation for the treatment of patients with steroid refractory acute graft-versus-host disease…
In early December 2020, the American Society of Hematology (ASH) held their Annual Meeting and Exposition. During the meeting, many companies presented data on clinical trials and treatments related…
ASH 2020: CRISPR and Vertex’s Potential Cure for Sickle Cell Disease and More Glimmers of Hope Published: Dec. 7, 2020 BioSpace CRISPR Therapeutics and Vertex Pharmaceuticals presented new data on…
Syndax Pharmaceuticals has plans to release data on axatilimab, a treatment for chronic graft-versus-host disease (cGVHD), at the 62nd American Society of Hematology (ASH) Annual Meeting, which will take place…
As reported in BioSpace, the FDA shocked Mesoblast executives, a stem-cell research company, when this October, they rejected the Biologics License Application (BLA) for the drug Ryoncil, meant to treat…
According to a story from BioSpace, the US Food and Drug Administration (FDA) recently announced that it has awarded grant funding that will go towards six clinical trials that will…
The United States FDA has just announced that they will be providing 6 new grants, which are worth 16 million dollars for rare disease research. These grants will last a…
The global biopharmaceutical company Incyte recently announced the first-ever recipient of its Incyte Ingenuity Award, which will be the Massachusetts General Cancer Center (MGCC). The purpose of this award is…
As originally shared in Tech Startups, an Israeli biotech company called Pluristem has created a placenta-based cell therapy to treat patients with COVID-19. So far, the therapy, which uses PLacental…
Chronic granulomatous disease (CGD) is a rare form of immunodeficiency. The most common form of this disease is X-linked chronic granulomatous disease (X-CGD) which is caused by a mutated CYBB gene. This…
Gareth Crabb is a thoughtful and caring six-year-old boy from Swansea, U.K. He is spending his second Christmas in the hospital this year, as he has anaplastic large cell…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
